Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas

Liya Yuan, Tracy C. Holmes, R. Edward Watts, Chaitan Khosla, Tom J. Broekelmann, Robert Mecham, Hong Zheng, Enrique W. Izaguirre, Keith M. Rich

Research output: Contribution to journalArticle

10 Scopus citations

Abstract

Glioblastomas display variable phenotypes that include increased drug-resistance associated with enhanced migratory and anti-apoptotic characteristics. These shared characteristics contribute to failure of clinical treatment regimens. Identification of novel compounds that promote cell death and impair cellular motility is a logical strategy to develop more effective clinical protocols. We recently described the ability of the small molecule, KCC009, a tissue transglutaminase (TG2) inhibitor, to sensitize glioblastoma cells to chemotherapy. In the current study, we synthesized a series of related compounds that show variable ability to promote cell death and impair motility in glioblastomas, irrespective of their ability to inhibit TG2. Each compound has a 3-bromo-4,5-dihydroisoxazole component that presumably reacts with nucleophilic cysteine thiol residues in the active sites of proteins that have an affinity to the small molecule. Our studies focused on the effects of the compound, ERW1227B. Treatment of glioblastoma cells with ERW1227B was associated with both down-regulation of the PI-3 kinase/Akt pathway, which enhanced cell death; as well as disruption of focal adhesive complexes and intracellular actin fibers, which impaired cellular mobility. Bioassays as well as time-lapse photography of glioblastoma cells treated with ERW1227B showed cell death and rapid loss of cellular motility. Mice studies with in vivo glioblastoma models demonstrated the ability of ERW1227B to sensitize tumor cells to cell death after treatment with either chemotherapy or radiation. The above findings identify ERW1227B as a potential novel therapeutic agent in the treatment of glioblastomas.

Original languageEnglish
Pages (from-to)207-219
Number of pages13
JournalJournal of Neuro-Oncology
Volume103
Issue number2
DOIs
StatePublished - Jun 1 2011

Keywords

  • Cell death
  • Cellular motility
  • Drug-resistance
  • ERW1227B
  • Focal adhesive complexes
  • Glioblastomas

Fingerprint Dive into the research topics of 'Novel chemo-sensitizing agent, ERW1227B, impairs cellular motility and enhances cell death in glioblastomas'. Together they form a unique fingerprint.

  • Cite this